Meeting
2021 ASCO Annual Meeting
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
Authors
Erika Richtig
Department of Dermatology, University of Graz, Graz, Austria
Erika Richtig , Ralf Gutzmer , Carmen Loquai , Jochen Utikal , Christoph Hoeller , Rudolf Stadler , Andrea Forschner , Jessica Cecile Hassel , Daniela Goeppner , Michael Fluck , Sebastian Haferkamp , Martin Kaatz , Manfred Welslau , Reinhard Dummer , Roger Anton Fredy Von Moos , Andrea Schmidt , Laura Milde , Olivier Michielin , Dirk Schadendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04045691
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9555)
DOI
10.1200/JCO.2021.39.15_suppl.9555
Abstract #
9555
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.
First Author: Ke Ji
Poster
2022 ASCO Annual Meeting
Meta-analysis of randomized phase II-III trials evaluating triplet combinations of immunotherapy and targeted therapy for BRAF V600-mutant unresectable or metastatic melanoma.
First Author: Pier Francesco Ferrucci